Merck's Covid-19 pill will probably get U.S. authorization despite disappointing efficacy data and concerns raised by regulators, Morgan Stanley analysts predicted

Merck's Covid-19 pill will probably get U.S. authorization despite disappointing efficacy data and concerns raised by regulators, Morgan Stanley analysts predicted https://t.co/dUSjITcEVt

— Bloomberg (@business) November 28, 2021